Drugs / EIS-12656
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06525298 | Sep 2024 → Sep 2027 expected | neoplasm | Eisbach Bio GmbH | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-05-06 | Eisbach Bio GmbH | Regulatory Eisbach Bio announces FDA clearance of IND application for EIS-12656, a first-in-class allosteric inhibitor of eisbach.bio ↗
has announced United States Food and Drug Administration (FDA) clearance of its investigational new drug (IND) application for EIS-12656 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-09-16 | Eisbach Bio GmbH | Eisbach announces first patient dosed in Phase 1/2 trial for EIS-12656, a first-in-class allosteric inhibitor eisbach.bio ↗ |
| 2024-05-06 | Eisbach Bio GmbH | Eisbach Bio announces FDA clearance of IND application for EIS-12656, a first-in-class allosteric inhibitor of eisbach.bio ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EIS-12656 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06525298 ↗ |
| Route | Oral | “EIS-12656 tablets given daily” NCT06525298 ↗ |